arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Emergent BioSolutions Inc.

EBS
$4.83 ▼ -0.47 (-8.87%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
65
Health
Fair
Bearish
auto_awesome

Analytical Summary

Emergent BioSolutions Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $250.7M
Dividend Yield
Revenue Growth -29.7%
Op. Margin 6.7%
ROIC 0.5%
FCF / Share $-0.70
Trailing P/E 37.2x
Price / Book 0.5x
FCF Yield
Debt / Equity 1.13
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$156.10M
↓ -29.7%
Net Income Profit after all expenses
$6.80M
↓ -90.0%
Operating Margin Operating profit as % of sales
6.7%
↑ +135.9% 64th
FCF / Share Free cash flow per share
$-0.70
↓ -156.4%
Long-Term Debt Long-term obligations
$589.70M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
68
Returns
68
Financial Health
43
Cash Quality
91

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters